Samsung Biologics Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 5.66%

Samsung Biologics Co Ltd (207940) has an Asset Resilience Ratio of 5.66% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Samsung Biologics Co Ltd to assess the company's strategic physical and investment asset allocation.

Liquid Assets

₩1.04 Trillion

≈ $703.39 Million USD Cash + Short-term Investments

Total Assets

₩18.34 Trillion

≈ $12.43 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Samsung Biologics Co Ltd's Asset Resilience Ratio has changed over time. See 207940 net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Samsung Biologics Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 207940 company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩1.04 Trillion	5.66%
Total Liquid Assets	₩1.04 Trillion	5.66%

Asset Resilience Insights

Limited Liquidity: Samsung Biologics Co Ltd maintains only 5.66% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Samsung Biologics Co Ltd Industry Peers by Asset Resilience Ratio

Compare Samsung Biologics Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Spyre Therapeutics Inc. NASDAQ:SYRE	Biotechnology	84.34%
3SBio Inc F:83B	Biotechnology	10.64%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Jiangxi Fushine Pharmaceutical Co Ltd SHE:300497	Biotechnology	0.02%
Novavax Inc NASDAQ:NVAX	Biotechnology	53.87%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for Samsung Biologics Co Ltd (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Samsung Biologics Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	5.42%	₩940.07 Billion ≈ $637.07 Million	₩17.34 Trillion ≈ $11.75 Billion	-5.10pp
2023-12-31	10.52%	₩1.69 Trillion ≈ $1.14 Billion	₩16.05 Trillion ≈ $10.87 Billion	-3.37pp
2022-12-31	13.89%	₩2.30 Trillion ≈ $1.56 Billion	₩16.58 Trillion ≈ $11.24 Billion	-2.73pp
2021-12-31	16.61%	₩1.32 Trillion ≈ $897.27 Million	₩7.97 Trillion ≈ $5.40 Billion	+3.79pp
2020-12-31	12.82%	₩823.60 Billion ≈ $558.14 Million	₩6.42 Trillion ≈ $4.35 Billion	+3.27pp
2019-12-31	9.55%	₩564.82 Billion ≈ $382.77 Million	₩5.91 Trillion ≈ $4.01 Billion	-9.02pp
2018-12-31	18.58%	₩1.11 Trillion ≈ $752.88 Million	₩5.98 Trillion ≈ $4.05 Billion	+18.26pp
2017-12-31	0.31%	₩22.61 Billion ≈ $15.32 Million	₩7.18 Trillion ≈ $4.87 Billion	-12.78pp
2016-12-31	13.09%	₩986.29 Billion ≈ $668.39 Million	₩7.53 Trillion ≈ $5.11 Billion	--

pp = percentage points

About Samsung Biologics Co Ltd

KO:207940 Korea Biotechnology

Market Cap

$31.37 Billion

₩46.29 Trillion KRW

Market Cap Rank

#857 Global

#17 in Korea

Share Price

₩1000000.00

Change (1 day)

+0.00%

52-Week Range

₩992000.00 - ₩1000000.00

All Time High

₩1000000.00